Search

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more

EHA welcomes European Parliament backing for SoHO legislation

EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.

Read more

SWG Educational Activities

EICMLThe 2023 EICML meeting took place in Naples in May 2023. Fifty-five physicians and scientists met at the Palazzo Alabardieri in central Naples to spend two days discussing emerging data and developing collaborations.

Read more

Community and Stakeholder Committee

Current committee members
Gianluca Gaidano, Italy (Chair)
Helen Papadaki, Greece (Chair)
Donal McLornan, United Kingdom (Vice-Chair)
Meritxell Alberich Jordà, Czech Republic (Councilor)
Arndt Borkhardt, Germany (Research Committee representative)
Raul Córdoba Mascuñano, Spain (Councilor)
Margarita Guenova, Bulgaria (Councilor)
Mandy Lauw, The Netherlands (YoungEHA representative)
Ivo Touw, The Netherlands (Education Committee…

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Highlights of Past EHA (HOPE) Asia 2020

October 16-17 2020
Meeting Chairs:

Dr N Senadheera (Sri Lanka College of Haematologists)
Prof J Gribben (European Hematology Association)

This second edition of HOPE Asia was presented together with the Sri Lanka College of Haematologists (SLCH) on October 16 and 17, 2020.…

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more